2696.HKライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (28 6月 2024 @ 17:08):
Our systems believe the stock currently is overvalued by -0.02% compare to its pairs and should correct downwards.

Shanghai Henlius Biotech, Inc., a biopharmaceutical company, engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases...

Stats
本日の出来高	1.81M
平均出来高	635 890
時価総額	12.23B
EPS	HKD0.250 ( Q4 \| 2023-12-31 )
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	21.36 (Sector) 0 (Industry) 6.31
ATR14	HKD0.0380 (0.17%)

0690.HK 0.00%

1061.HK -0.82%

1167.HK 3.31%

1177.HK -1.11%

1228.HK 0.00%

1477.HK 1.63%

1521.HK -2.44%

1530.HK 2.71%

1548.HK -1.42%

1672.HK -3.61%

1873.HK 0.00%

1875.HK -0.45%

1877.HK -0.51%

1952.HK -2.59%

2096.HK -0.69%

2126.HK -2.00%

2137.HK -0.98%

2142.HK 1.47%

2157.HK -3.80%

2162.HK -2.88%

2171.HK -2.04%

2179.HK -3.00%

2197.HK -1.45%

2256.HK -0.61%

2257.HK 0.00%

2616.HK 2.70%

2696.HK -0.65%

3759.HK -1.63%

6160.HK 1.17%

6600.HK 0.86%

6622.HK 0.71%

6628.HK 1.33%

6821.HK -0.10%

6826.HK 1.76%

6978.HK 23.00%

6996.HK 0.00%

6998.HK 0.00%

9688.HK -0.15%

9926.HK -2.33%

9939.HK -4.59%

9966.HK -0.41%

9969.HK 3.66%

9995.HK -4.67%

相関 (AI algo v.1.1b): Overvalued: -0.02% HKD22.85 paired level. (アルゴリズムは、最も相関の高い株式の変更をリアルタイムで追跡し、即時の更新を提供します)

ボリューム相関

長: -0.03 (neutral)

短: 0.25 (neutral)

Signal:(52.689) Neutral

Shanghai Henlius Biotech 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Shanghai Henlius Biotech 相関 - 通貨/商品

0.61
( weak )

-0.31
( neutral )

0.00
( neutral )

0.70
( moderate )

-0.63
( weak negative )

-0.54
( weak negative )

Shanghai Henlius Biotech 財務諸表

Annual	2023
収益:	HKD5.39B
総利益:	HKD3.92B (72.64 %)
EPS:	HKD1.010

FY	2023
収益:	HKD5.39B
総利益:	HKD3.92B (72.64 %)
EPS:	HKD1.010

FY	2022
収益:	HKD3.21B
総利益:	HKD2.37B (73.73 %)
EPS:	HKD-1.280

FY	2021
収益:	HKD1.68B
総利益:	HKD1.16B (68.93 %)
EPS:	HKD-1.858

Financial Reports:

No articles found.

Shanghai Henlius Biotech Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Shanghai Henlius Biotech

Shanghai Henlius Biotech, Inc., a biopharmaceutical company, engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating non-hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection to treat metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. The company also develops Serplulimab to treat squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, metastatic esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, nsNSCLC, squamous cell carcinoma of the head and neck (SCCHN), and solid tumors; HLX04-O, a bevacizumab injection for wet age-related macular degeneration; HLX22 to treat breast and metastatic gastric cancer; HLX07, HLX23, HLX35, HLX208, HLX55, HLX301, and HLX20 for the treatment of solid tumors; HLX11 to treat breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; HLX12 for gastric cancer, metastatic non-small cell lung cancer, and mCRC; and HLX14 to treat osteoporosis. In addition, it develops HLX26 for the treatment of solid tumor and lymphoma; HLX13 to treat melanoma, renal cell carcinoma, and mCRC; HLX15 for multiple myeloma; and HLX71 to treat COVID-19. Shanghai Henlius Biotech, Inc. operates in Mainland China, Europe, rest of Asia Pacific, and internationally. The company was founded in 2010 and is headquartered in Shanghai, China. Shanghai Henlius Biotech, Inc. is a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.